New worries should not distract executives from addressing rising costs and threats of consolidations
Medicare Advantage will take the greatest hit: Plans must reduce their medical costs by almost 25% over seven years just to maintain current profitability.
To address these challenges, plans should follow a three-pronged approach:
NEW WAY OF DOING BUSINESS
Firms in growth mode will also re-examine their business models. They may, for example, change their target customers and develop new offerings for them, including non-insurance products. To make decisions best suited for their market and risk tolerance, firms must develop an objective view of their organization's capabilities, an accurate model of their ecosystem, and a realistic prediction of likely future market scenarios.
The boldest firms are already moving toward a new way of doing business in which the health plan is an active partner of both providers and members. This represents a major departure from the current détente between payers and providers, with important implications for human capital, information systems and other investments.
Given the magnitude of the recent reforms, payers that blindly adhere to their current strategic plans could face stagnation or collapse. Firms that revisit their strategies, however, will be positioned to thrive in the new system as it evolves.
Jeff Gruen is a director at PRTM, a global consulting firm.
Cassandra Earley is an associate at PRTM.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More